LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

Search

Puma Biotechnology Inc

Suletud

SektorTervishoid

5.84 -2.34

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.8100000000000005

Max

5.99

Põhinäitajad

By Trading Economics

Sissetulek

3M

12M

Müük

21M

76M

P/E

Sektori keskmine

10.197

61.417

Kasumimarginaal

15.633

Töötajad

179

EBITDA

13M

27M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-16.67% downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-42M

316M

Eelmine avamishind

8.18

Eelmine sulgemishind

5.84

Uudiste sentiment

By Acuity

50%

50%

153 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. märts 2026, 23:12 UTC

Kuumad aktsiad

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12. märts 2026, 22:15 UTC

Tulu

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12. märts 2026, 21:42 UTC

Uudisväärsed sündmused

Stryker Says Cyberattack Disruption Is Continuing

12. märts 2026, 21:29 UTC

Uudisväärsed sündmused

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12. märts 2026, 21:27 UTC

Tulu

Adobe CEO to Depart as AI Boosts Sales -- Update

12. märts 2026, 20:46 UTC

Tulu

Adobe Posts Higher Sales With CEO Set to Depart

12. märts 2026, 20:21 UTC

Uudisväärsed sündmused

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12. märts 2026, 23:57 UTC

Market Talk

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12. märts 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. märts 2026, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12. märts 2026, 22:13 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

12. märts 2026, 22:13 UTC

Market Talk
Tulu

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12. märts 2026, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12. märts 2026, 21:04 UTC

Tulu

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Sales $865M >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Net $558.3M >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12. märts 2026, 20:57 UTC

Market Talk
Uudisväärsed sündmused

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12. märts 2026, 20:10 UTC

Tulu

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12. märts 2026, 20:05 UTC

Tulu

Adobe 1Q Rev $6.4B >ADBE

12. märts 2026, 20:05 UTC

Tulu

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-16.67% langus

12 kuu keskmine prognoos

Keskmine 5 USD  -16.67%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

0

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

153 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat